POPULARITY
3 episodes with kite pharma
3 episodes with kite pharma
8 episodes with kite pharma
3 episodes with kite pharma
2 episodes with kite pharma
2 episodes with kite pharma
2 episodes with kite pharma
10 episodes with kite pharma
2 episodes with kite pharma
In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adriana Herrera, CEO at Pierre Fabre Pharmaceuticals (USA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adriana, covering: Why Big Pharma is such a great training ground for future pharma leaders, and how a period living and working in Mexico defined her leadership style The reality of being purchased by a big pharma like Gilead, and retaining independence as the acquired company, Kite Pharma The opening of a market opportunity that led Adriana to her first CEO role, and how the role is pushing her outside of her comfort zone Why she is optimistic about the future of manufacturing and commercialising cell therapies - innovation will find a way, but it takes time How the current geopolitical environment is adding more risk and uncertainty to an industry plagued with risk... and how that may impact investments and supply chains Adriana leads the expansion of Pierre Fabre's US presence in precision oncology, cell therapy and rare diseases with an immediate focus on the commercialization of a groundbreaking allogenic cell therapy. Most recently, Adriana served as U.S. General Manager at Kite Pharma where she successfully commercialized the autologous CART-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for U.S. Oncology and high-impact leadership roles at Novartis Oncology including Vice President and Global Diseases Lead for Lung and Genitourinary cancers. Adriana commenced her career at Bristol Myers-Squibb. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
In this episode of Let's Talk Quality, Hemish speaks with Jose Caraballo, a biotech leader with over 30 years of experience in process engineering, manufacturing science, and quality leadership.Jose started his career in process engineering, optimizing yields and scaling up production. Over time, he made a deliberate shift into quality leadership, recognizing that understanding the external side of the business - suppliers, regulators, and customers, was just as important as technical expertise.Now, as a VP of Quality at Kite Pharma, a leader in cell therapy manufacturing, Jose is deeply involved in shaping the future of quality in biotech and remains passionate about driving innovation and leadership in the biotech space. In this conversation we cover:✅ The shift from compliance-focused quality to strategic quality leadership✅ Why quality is a company-wide responsibility, not just a QA function✅ How moving from technical roles to quality leadership can accelerate career growth✅ The importance of curiosity and adaptability in biotech✅ How CGT is changing expectations for speed, risk management, and patient impact✅ The role of automation and AI in quality systems✅ Lessons from moving into senior leadership and managing teams effectively✅ What biotech companies need to focus on to embed quality culture at every levelJose's career journey is a great example of how technical expertise, business strategy, and leadership all come together to drive impact in biotech.
As the use of chimeric antigen receptor (CAR) T-cell therapy continues to expand as an effective treatment for hematologic malignancies, understanding how to identify eligible patients early and implementation of an effective framework for identification can improve care coordination and better prepare community cancer programs for widespread use of CAR T-cell therapy. In this episode, CANCER BUZZ speaks with David L. Porter, MD, director of Cell Therapy and Transplant at Penn Medicine, about the challenges community oncologists face and the key role they can play in identifying and recommending eligible patients for CAR T-cell therapy. “The single most important thing for a patient out in the community at a place that doesn't have familiarity or immediate access to CAR T-cells is to refer them somewhere that does and refer them soon and timely.” – David L. Porter, MD Guest: David L. Porter, MD Director, Cell Therapy and Transplant Jodi Fisher Horowitz Professor in Leukemia Care Excellence Penn Medicine- University of Pennsylvania Health System (UPHS) Philadelphia, PA This episode has been developed in connection with the ACCC education program Tips for Early Patient Identification for CAR T-Cell Therapy and Creating “Stickiness” with Community Providers for Optimal Care Coordination. This episode was made possible with support by Kite Pharma. Additional Reading/Sources ACCC Oncology Issues Article If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary Essentials for Identifying Patients – Bringing CAR T-cell Therapy to Community Oncology Optimizing Care Coordination – Bringing CAR T-cell Therapy to Community Oncology
Translating the therapeutic promise of cell and gene therapies into clinical reality relies on robust potency assays. However, designing assays that accurately reflect the complex mechanisms of these therapies can feel like chasing a moving target. Here, Charlotte Barker, Editor, Cell & Gene Therapy Insights, speaks with Giorgio Zenere, CMC technical project lead in the Global QC Technology Innovation Team, Kite Pharma, and Dirk Windgassen, Director of Analytical Development, Miltenyi Biotec, to discuss best practices and future trends in developing potency assays for cell and gene therapies.
Improving timely identification and referral of patients who may be eligible for chimeric antigen receptor (CAR) T-cell therapy is critical for improving outcomes for patients with hematologic malignancies. On February 7, 2024, ACCC hosted a virtual Working Summit: Advancing CAR T-Cell Therapy Care Continuity and Collaborative Patient Education to explore topics including patient and caregiver needs as well as care coordination between referring providers and certified CAR T-cell therapy centers. In this episode, CANCER BUZZ speaks with Amy D. Smith, FNP-BC, director of the Meredith and Jeannie Ray Cancer Center at Ivinson Memorial Hospital and co-chair of the Summit about the event's key findings, which can guide cancer programs in building a framework for optimized CAR T-cell therapy care coordination. “The goal really was how do we get those patients [receiving CAR T-cell therapy] back here and get them back into some kind of normalcy in their life sooner? A lot of that is building relationships and having trust with those providers in the academic centers that are performing the CAR T, so that they know that we can provide safe care at home.” –Amy D. Smith, FNP-BC “Keeping care close to home is near to my heart, living in a rural area. That was one takeaway... how do we collaborate better to make this happen for our patients and care teams? –Amy D. Smith, FNP-BC Amy D. Smith, FNP-BC Director, Meredith and Jeannie Ray Cancer Center Ivinson Memorial Hospital Laramie, WY This episode was developed in connection with the ACCC education program Tips for Early Patient Identification for CAR T-Cell Therapy and Care Continuity with Community Providers and made possible with support by Kite Pharma, Johnson & Johnson, and Legend Biotech, and through partnerships with Cancer Support Community, the Association of American Cancer Institutes, and the Advanced Practitioner Society for Hematology and Oncology. Resources: ACCC CAR T-Cell Therapy Focus Group Highlights Tips for Early Patient Identification for CAR T-Cell Therapy and Care Continuity with Community Providers Community CAR T-Cell Patient Identification Framework – CANCER BUZZ [Mini Podcast] Ep 138 If They Recur, You Should Refer—A Community Oncologist Patient ID Roundtable Summary – from Oncology Issues Vol. 38, No. 6
This is very special episode. I was joined by Laurie Adami, a financial services exec who was forced to give up her career after a cancer diagnosis in 2006. After a 12 year battle fighting follicular non-Hodgkin lymphoma, and six lines of therapy, Laurie received a call from her oncologist, informing her about a new therapy called CAR-T, that was being developed by Kite Pharma.They were opening a clinical trial at UCLA with five patients. Laurie was to be patient number one. One month after her CAR-T treatment, Laurie was in complete remission.Laurie is now focused on patient advocacy, volunteering and fundraising for cancer research, especially CAR-T immunotherapy. I wanted to speak with Laurie, to talk about her fight against follicular non-Hodgkin lymphoma, how she learnt about a new game-changing therapy called CAR-T, and some key issues around access to patients, safety concerns raised by the FDA, bridging the gap between industry and patients, and what she is doing now to raise awareness of the benefits and potential of CAR-T. We discuss the following:[2:40] Laurie's Diagnosis, Initial Treatment and Challenges[5:00] 12 Year Cycle of Six Lines of Therapy and Relapse [10:55] Hearing the Story of Emily Whitehead and CAR-T in 2012[14:22] Starting Sixth Line of Therapy in 2016 [14:57] Receiving a call about a CAR-T Trial in Spring, 2018[18:55] Going Through CAR-T Cell Therapy[21:32] Complete Remission[24:18] Becoming a Patient Advocate Volunteer[26:41] Patient Access and Challenges[35:41] Laurie's Response to the FDA Safety Advisory on CAR-T [41:30] Bridging the Gap Between Industry and Patients[46:16] The Potential and Future of CAR-T Therapy[51:34] Living Life to the Full[58:41] Meeting the People that Saved Her Life I really hope people enjoy listening to Laurie's story and that it gives hope to anyone affected by Cancer, and raises awareness of the potential for CAR-T Cell Therapy to save more lives.There are a number of challenges that Laurie is on a mission to tackle, and I would urge people to listen to this episode to learn more about how we can bridge the gap between the industry and patients, and get safter, faster and more affordable access of these therapies to more patients like Laurie.Thank you Laurie for sharing your story with us!
Last November UIS Innovate Springfield and the Community Foundation for the Land of Lincoln hosted a public event titled “The Next Technology Revolution,” which featured, Springfield native and Vice Chairman for equity private markets at Jefferies' Global Technology Investment Banking Group, Cully Davis.Davis has nearly 30 years of investment banking experience and worked with numerous businesses known for being on the cutting edge of technology including, Google, Groupon, Lyft, Box, Kite Pharma, MicroStrategy, and SunPower to name a few. At this event, Davis shared lessons he's learned in Silicon Valley and the elements needed to make Springfield the home of the next technology revolution.
This week I was joined by Vaishali Shukla, VP of Global Quality Manufacturing at Kite Pharma."Act locally but think globally”. This is the mindset that Vaishali has helped instil in her role to help harmonize processes, engage the global network, and create a 'one team' quality approach.Vaishali talks us through her journey in quality and some of the challenges of leading a global quality operation of 500+ people, and the key aspects which have helped her to get to where she is now. We discuss the below points:The challenges of managing a global quality operation.Navigating the pandemic and transitioning into a remote world.Managing people in time-zones across the US, Europe, and Asia.Staying relevant with guidelines across different jurisdictions.Balancing compliance and innovation in the cell therapy industry.How to manage M&A and the complex transition that takes place. The evolution of guidelines and technology over the past two decades.How to stay relevant in a constantly evolving landscape.The skills Vaishali has developed to progress to where she is now.Vaishali's outlook on leadership, and within the ATMP space.Whether you want to work in a global operation or small biotech, this is a must listen for any current or aspiring quality leader. So many great insights into the mindset of a highly successful quality leader and some key traits to help accelerate your own leadership career.I hope you enjoy the show!
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MQE865. CME credit will be available until December 31, 2024.Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision MedicinePenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and the HealthTree Foundation for Acute Myeloid Leukemia.SupportThis activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.DisclosuresSergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Johnson & Johnson, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Johnson & Johnson, Inc.; Miltenyi Biotec; Sanofi; and Takeda Pharmaceutical Company Limited.Selina Luger, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Amgen Inc.; Bristol Myers Squibb; and Marker Therapeutics, Inc.Grant/Research Support from Onconova Therapeutics, Inc.Speaker for Amgen Inc.Pinkal Desai, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Laboratories.Ghayas Issa, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Kura Oncology, Inc. and Novartis Pharmaceuticals Corporation.Grant/Research Support from Cullinan Oncology, Inc; Kura Oncology, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Syndax.Tapan Kadia, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Daiichi Sankyo Inc.; Genentech, Inc.; Genzyme Corporation; Jazz Pharmaceuticals, Inc.; Liberum Capital Limited; Novartis Pharmaceuticals Corporation; Pfizer; PinotBio, Inc.; Pulmotect, Inc.; Sanofi; Servier Laboratories.Grant/Research Support from AbbVie; Amgen Inc.; Ascentage Pharma Group; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Cellenkos Inc.; Cyclacel Pharmaceuticals, Inc.; Delta-Fly Pharma, Inc.; Genentech, Inc.; GenFleet Therapeutics; GlycoMimetics; Iterion Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Pfizer; Pulmotect, Inc.; Regeneron Pharmaceuticals Inc.; and SELLAS Life Sciences Group. Grant/Research Support Paid to Institution.Speakers Bureau participant with Biologix USA, Inc.; CURE Pharmaceutical; and Hikma Pharmaceuticals.Honorarium from Genzyme Corporation.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MQE865. CME credit will be available until December 31, 2024.Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision MedicinePenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and the HealthTree Foundation for Acute Myeloid Leukemia.SupportThis activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.DisclosuresSergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Johnson & Johnson, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Johnson & Johnson, Inc.; Miltenyi Biotec; Sanofi; and Takeda Pharmaceutical Company Limited.Selina Luger, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Amgen Inc.; Bristol Myers Squibb; and Marker Therapeutics, Inc.Grant/Research Support from Onconova Therapeutics, Inc.Speaker for Amgen Inc.Pinkal Desai, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Laboratories.Ghayas Issa, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Kura Oncology, Inc. and Novartis Pharmaceuticals Corporation.Grant/Research Support from Cullinan Oncology, Inc; Kura Oncology, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Syndax.Tapan Kadia, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Daiichi Sankyo Inc.; Genentech, Inc.; Genzyme Corporation; Jazz Pharmaceuticals, Inc.; Liberum Capital Limited; Novartis Pharmaceuticals Corporation; Pfizer; PinotBio, Inc.; Pulmotect, Inc.; Sanofi; Servier Laboratories.Grant/Research Support from AbbVie; Amgen Inc.; Ascentage Pharma Group; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Cellenkos Inc.; Cyclacel Pharmaceuticals, Inc.; Delta-Fly Pharma, Inc.; Genentech, Inc.; GenFleet Therapeutics; GlycoMimetics; Iterion Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Pfizer; Pulmotect, Inc.; Regeneron Pharmaceuticals Inc.; and SELLAS Life Sciences Group. Grant/Research Support Paid to Institution.Speakers Bureau participant with Biologix USA, Inc.; CURE Pharmaceutical; and Hikma Pharmaceuticals.Honorarium from Genzyme Corporation.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MQE865. CME credit will be available until December 31, 2024.Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision MedicinePenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and the HealthTree Foundation for Acute Myeloid Leukemia.SupportThis activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.DisclosuresSergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Johnson & Johnson, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Johnson & Johnson, Inc.; Miltenyi Biotec; Sanofi; and Takeda Pharmaceutical Company Limited.Selina Luger, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Amgen Inc.; Bristol Myers Squibb; and Marker Therapeutics, Inc.Grant/Research Support from Onconova Therapeutics, Inc.Speaker for Amgen Inc.Pinkal Desai, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Laboratories.Ghayas Issa, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Kura Oncology, Inc. and Novartis Pharmaceuticals Corporation.Grant/Research Support from Cullinan Oncology, Inc; Kura Oncology, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Syndax.Tapan Kadia, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Daiichi Sankyo Inc.; Genentech, Inc.; Genzyme Corporation; Jazz Pharmaceuticals, Inc.; Liberum Capital Limited; Novartis Pharmaceuticals Corporation; Pfizer; PinotBio, Inc.; Pulmotect, Inc.; Sanofi; Servier Laboratories.Grant/Research Support from AbbVie; Amgen Inc.; Ascentage Pharma Group; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Cellenkos Inc.; Cyclacel Pharmaceuticals, Inc.; Delta-Fly Pharma, Inc.; Genentech, Inc.; GenFleet Therapeutics; GlycoMimetics; Iterion Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Pfizer; Pulmotect, Inc.; Regeneron Pharmaceuticals Inc.; and SELLAS Life Sciences Group. Grant/Research Support Paid to Institution.Speakers Bureau participant with Biologix USA, Inc.; CURE Pharmaceutical; and Hikma Pharmaceuticals.Honorarium from Genzyme Corporation.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MQE865. CME credit will be available until December 31, 2024.Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision MedicinePenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and the HealthTree Foundation for Acute Myeloid Leukemia.SupportThis activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.DisclosuresSergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Johnson & Johnson, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Johnson & Johnson, Inc.; Miltenyi Biotec; Sanofi; and Takeda Pharmaceutical Company Limited.Selina Luger, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Amgen Inc.; Bristol Myers Squibb; and Marker Therapeutics, Inc.Grant/Research Support from Onconova Therapeutics, Inc.Speaker for Amgen Inc.Pinkal Desai, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Laboratories.Ghayas Issa, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Kura Oncology, Inc. and Novartis Pharmaceuticals Corporation.Grant/Research Support from Cullinan Oncology, Inc; Kura Oncology, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Syndax.Tapan Kadia, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Daiichi Sankyo Inc.; Genentech, Inc.; Genzyme Corporation; Jazz Pharmaceuticals, Inc.; Liberum Capital Limited; Novartis Pharmaceuticals Corporation; Pfizer; PinotBio, Inc.; Pulmotect, Inc.; Sanofi; Servier Laboratories.Grant/Research Support from AbbVie; Amgen Inc.; Ascentage Pharma Group; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Cellenkos Inc.; Cyclacel Pharmaceuticals, Inc.; Delta-Fly Pharma, Inc.; Genentech, Inc.; GenFleet Therapeutics; GlycoMimetics; Iterion Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Pfizer; Pulmotect, Inc.; Regeneron Pharmaceuticals Inc.; and SELLAS Life Sciences Group. Grant/Research Support Paid to Institution.Speakers Bureau participant with Biologix USA, Inc.; CURE Pharmaceutical; and Hikma Pharmaceuticals.Honorarium from Genzyme Corporation.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.
As the use of chimeric antigen receptor (CAR) T-cell therapy continues to expand as an effective treatment for hematologic malignancies, understanding how to identify eligible patients early and implementation of an effective framework for identification can improve care coordination and better prepare community cancer programs for widespread use of CAR T-cell therapy. In this episode, CANCER BUZZ speaks with David L. Porter, MD, director of Cell Therapy and Transplant at Penn Medicine, about the challenges community oncologists face and the key role they can play in identifying and recommending eligible patients for CAR T-cell therapy. “The single most important thing for a patient out in the community at a place that doesn't have familiarity or immediate access to CAR T-cells is to refer them somewhere that does and refer them soon and timely.” – David L. Porter, MD Guest: David L. Porter, MD Director, Cell Therapy and Transplant Jodi Fisher Horowitz Professor in Leukemia Care Excellence Penn Medicine- University of Pennsylvania Health System (UPHS) Philadelphia, PA This episode has been developed in connection with the ACCC education program Tips for Early Patient Identification for CAR T-Cell Therapy and Creating “Stickiness” with Community Providers for Optimal Care Coordination. This episode was made possible with support by Kite Pharma. Additional Reading/Sources If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary Essentials for Identifying Patients – Bringing CAR T-cell Therapy to Community Oncology Optimizing Care Coordination – Bringing CAR T-cell Therapy to Community Oncology
In this episode of Evaluating Biopharma, host Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Jonathan Tsang, Senior Director, Manufacturing Sciences & Technology at Kite Pharma, who shares his experiences and provides advice on how autologous cell therapy companies can better prepare for commercial manufacturing, including: addressing the challenge of variability of patient cell behavior, process development characterization using healthy donor vs. patient cells, volume and logistical complexity of personalized therapy, and planning and implementing fast and efficient business systems to support scale-out. He also discusses critical quality attributes he looks for during process development and his thoughts on developing processes that can cope with variability in reagents, media, and more. Links from this episode: Evaluating Biopharma Black Diamond Networks Kite Pharma Evaluating Biopharma boiler: Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today's decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Evaluating Biopharma digital and educational networking events.
To mark the final episode of Season 4, Isabel and Jade reminisce about their favourite moments from the series and give an exclusive teaser for the next issue of GOLD – out on 13 April. Expect discussion on topics such as the current state of life sciences innovation in the UK, the latest advances and potential of personalised medicine, a deep dive into our Catalyst interview with Christi Shaw, former CEO, Kite Pharma, and lots of bonus insights from the writers themselves. Be sure to subscribe here to receive the full issue straight to your inbox on publication day.
In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition. Mikkael A. Sekeres, MD, MS, chief of the division of hematology and professor of medicine at Sylvester Comprehensive Cancer Center and University of Miami Health System and chair of the ASH committee on communications, discusses some key take-home points from the Long COVID presentation. :00 Shakira J. Grant, MBBS, discusses multilevel interventions required to increase the rate at which Black individuals participate in hematology research studies. 3:44 Arushi Khurana, MBBS, reviews criteria used to disqualify patients from participating in front-line clinical trials, the acceptable ranges of which often prohibited Black and Hispanic patients from enrollment. 6:35 Tatyana Feldman, MD, discusses how the addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma. 9:32 Warren B. Fingrut, MD, reviews how hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry. 12:02 Read the full coverage here: Restrictive diet an 'unnecessary burden' for patients undergoing HSCT Multilevel interventions needed to reduce racial disparities in clinical trial enrollment Eligibility criteria more likely to exclude minorities from lymphoma clinical trials Combination ‘promising' for advanced classical Hodgkin lymphoma Non-European HSCT recipients undergo more complex procedures with fewer resources Disclosures: Feldman reports consulting/advisory roles with, speakers bureau roles with or other financial relationships with AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genmab, Genomic Testing Cooperative, Janssen, Karyopharm Therapeutics, Kite Pharma, MorphoSys, Pharmacyclics, Secura Bio, Seagen and Takeda. Please see the abstract for all other researchers' relevant financial disclosures. Fingrut reports no relevant financial disclosures. Please see the abstract for all other researchers' relevant financial disclosures. Grant reports no relevant financial disclosures. Please see the abstract for all other researchers' relevant financial disclosures. Khurana reports no relevant financial disclosures.
Host Dr. John Sweetenham, of the UT Southwestern Harold C. Simmons Comprehensive Cancer Center, and Dr. Eduardo Sotomayor, director of the cancer institute at Tampa General Hospital, discuss the impact of Hurricane Ian on cancer care in Florida, and the importance of disaster preparedness to protect patients and clinicians in regions prone to natural disasters. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the associate director for Clinical Affairs at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center, and host of the ASCO Daily News podcast. Hurricane Ian, a large and destructive Category 4 hurricane, has caused fatalities and widespread damage in Florida after causing huge destruction in Cuba. Communities in the hardest-hit areas have been destroyed, and hospitals across the state have been forced to evacuate patients. Today, I will be speaking with Dr. Eduardo Sotomayor, the director of the Cancer Institute at Tampa General Hospital, about the impact of the hurricane on cancer care. Our full disclosures are available on the transcript of this episode, and disclosures relating to all episodes of the ASCO Daily News podcast are available on our transcripts at asco.org/podcasts. Dr. Sotomayor, thanks for being on the podcast today. Dr. Eduardo Sotomayor: Thank you, John, and the ASCO Daily News Podcast, for having me. Dr. John Sweetenham: To begin with, Dr. Sotomayor, could you tell us a little about how Hurricane Ian impacted cancer care at your institution, and how soon do you think you'll have all of your cancer services restored? Dr. Eduardo Sotomayor: Thank you for the opportunity to talk to you about the effect of Hurricane Ian on the state of Florida. But before we start, I would like to say that our thoughts and our prayers are for those Florida citizens who were severely affected by this hurricane, in particular, our cancer patients and their caregivers. So, Tampa General Hospital is located on Davis Islands. So, we were at high risk for having inundation, major destruction, and disruptions in cancer care if the hurricane hit us directly. We were blessed that at the last minute, the hurricane changed its path. But it's important to emphasize all of the preparation that took place, starting seven days before the potential landfall of the hurricane in the state of Florida. This started at the highest levels of the hospital, with the senior leaders getting together as well as the leaders of the cancer institute. We have different scenarios that we call scenario A, B, and C. So, scenario A was the worst-case scenario that we would have a direct hit, then one or two floors of the cancer institute and the hospital would be under water. So, for that scenario, we knew that we needed to be ready to move cancer care to other facilities that Tampa General has inland in areas called Riverview and Brandon. So, scenario C is the scenario that fortunately for us, was the scenario that we dealt with during the storm. We didn't have a direct hit; we had only minimal damage, and we were able to reopen our doors 48 hours after the storm hit Florida. Important to mention also is that during those 48 hours, there was significant disruption in cancer care. In the inpatient service, we had to decrease the number of inpatients to keep those patients that really needed to be in the hospital. We closed all our outpatient facilities and therefore needed to call every patient to let them know about the cancellation of appointments, but also re-scheduling those appointments for the days after the storm has passed. As I said, again, we were among the lucky cancer centers in the state of Florida, but south of us, there were hospitals and community oncology practices that were severely affected by Hurricane Ian. Dr. John Sweetenham: So, it sounds to some extent, Dr. Sotomayor, as if your institution kind of dodged a bullet, although clearly people south of you were very badly affected. But I'm assuming that there had been some disruptions to care for your patients. Can you comment a little on that, and what you're doing to address the disruptions to care, assuming that you experienced some, even though you didn't take a direct hit. Dr. Eduardo Sotomayor: What we have learned from this experience is that preparation is extremely important. Within 24 hours, we created a command center, an operations team, our logistics team, safety team, and we started canceling those appointments that were not critical. When we knew that the hurricane was coming in our direction, then we had to cancel all of our operations. But then we had meetings twice a day with different members of our team to start making phone calls also regarding cancellation of appointments. And then, as the days passed, we started to adapt our plans and starting calling back patients. What is important, I think a silver lining of the COVID-19 pandemic, has been the availability of telehealth, of easy communication with patients. I think that patients are now savvier with managing telehealth. So, the days after the hurricane hit us, we had some patients that had to come back to receive chemotherapy infusions or radiation, but the large priority of patients were able to manage via telehealth. Dr. John Sweetenham: Yes. Thank you. I know one of the questions that I was going to ask you a little later on was whether the telehealth infrastructure that was developed during the COVID-19 pandemic was helpful in response to the hurricane, and clearly from your comments, it has made it easier in terms of patients' familiarity with the platform and so on. So, that's good to know. Dr. Eduardo Sotomayor: Right. And also, just to add to that is that technology before the COVID-19 pandemic, when we were facing a similar situation. Basically, all our call centers would be closed. So, these days we have technology in which employees or members of our team that were receiving or making phone calls, now can do through through special apps in case the internet goes down or electricity goes down. Still, now there are systems that can allow temporary communication with patients in a timelier way. Dr. John Sweetenham: Yeah, that's very reassuring. The Florida Hospital Association has said that many hospitals are feeling capacity pressure. Can you comment on what the Tampa General Hospital is able to help by perhaps offloading other institutions that were badly damaged in the storm, particularly those in the Southwest of Florida? Dr. Eduardo Sotomayor: Yeah, that's a very important question. I think that when we knew that we would be okay and there would not be a significant impact of the hurricane on our facilities, we changed our course and started calling our partners in the oncology community, private practice groups, Florida Cancer Specialists that have offices and provide cancer care in those areas that were severely affected by the hurricane. We are working together. One of the things that I have learned is that a significant percentage of cancer care is performed in the community. Communities were affected by this hurricane and therefore I think it is important to keep that open communication between academic centers and oncology practice in the community. With reference to your question, Tampa General has six helicopters; it has a command center and as soon as it was safe for our helicopters to travel, they went to these affected areas. There were hospitals near our region that didn't have electricity or water. I am proud of the service provided by Tampa General Hospital to other hospitals and cancer care communities that were severely affected by the hurricane. I think so far, we were able to transfer between 50 to 70 patients who were in critical condition and needed to be removed from those areas that were significantly affected by the hurricane. And I have to say, Tampa General Hospital is just one of the hospitals that responded; all of the hospitals in the state of Florida joined a forces to help our patients in general during these difficult times. Dr. John Sweetenham: Yeah, it's certainly great to hear of the oncology community and healthcare community in general coming together to overcome the challenges for so many of these patients. You know, one of the challenges that occurs to me, which might be an issue for you because of your increased patient volumes, as well as for those centers that are more directly affected by the hurricane, and that's the issue of supply chain and availability of medicines, and particularly chemotherapy and other antineoplastic drugs. Can you comment on whether you are experiencing any supply chain issues with medicines, or whether you're aware of other organizations in the southern part of Florida who are having those challenges at the moment? Dr. Eduardo Sotomayor: So, there are two answers to your question; if we are lucky to be in urban communities, I think that the supply chain was not significantly affected, but the problem has been in the rural communities in Florida. And unfortunately, in addition to the areas near the ocean, including Fort Myers, Naples, and Port Charlotte, the track of the hurricane through Florida affected the rural communities. And in those rural communities the problem was flooding, several trees went down, access in those areas was problematic, and they are still dealing with significant issues in the supply chain. What we are doing as are all the other big centers, is trying to do our best to either provide those supplies to these affected areas or to transfer some of the patients from those areas to, I would say, urban hospitals that have more capacity. Dr. John Sweetenham: So, this raises, I think, a really important issue. We know that very typically underserved communities are disproportionately impacted when there are natural disasters. And to your point, it's clear that you've seen the potential for significant disruption to rural versus urban communities as a result of the hurricane. Do you have any other thoughts or maybe any other examples of how disproportionate care may have arisen because of the effects on underserved communities? Dr. Eduardo Sotomayor: Even before any natural disasters, rural communities-- and I want to focus on rural communities in the state of Florida because there is a significant number of Floridians that live in rural communities. And if you look at the incidence of cancer and mortality associated with cancer in those rural communities, it is greater than the mortality that occurs in urban areas or big cities. So, number one. And there are several issues; there is transportation, access to care, very few oncology providers in those areas. So, even before the natural disaster that just happened, those communities were significantly disadvantaged. And unfortunately, not only the hurricane affected those rural areas, but now I would say the few organizational capabilities that they have have been further impacted. So therefore, when we think about the impact of the hurricane in the state of Florida, we should also be thinking about our rural communities. They are the ones that are going to take longer, perhaps months, or even a year, to recover from the significant damage that Hurricane Ian has imposed upon those communities. Dr. John Sweetenham: Thanks. Switching gears a little, are you concerned about the disruption of research and clinical trials in parts of Florida in the months ahead? I'm just thinking with issues such as-- you know, initially it will be scheduling of treatments, perhaps the transportation disruption, and so on. Do you see these as being potential threats to clinical trial activity in the state for the coming months, and possibly years? Dr. Eduardo Sotomayor: So again, I think that clinical trials in big centers, in urban areas are going to be able to recover relatively quickly. I mean, for instance, our clinical trials operation is back to normal, and was not affected. So, there is a big community oncology practice in the state of Florida, Florida Cancer Specialists, especially if they have active clinical trials, but they have locations in several of the areas that were significantly affected by the hurricane. So, I think in those areas, it is going to take time to recover. But in my early conversations with our colleagues, Florida Cancer Specialists especially, they're going to be moving some clinical trials operations from those affected areas to areas that are fully functional. But definitely, there is going to be a disruption, yes. And unfortunately, that disruption is going to affect those patients enrolled in clinical trials that live in underserved areas, and in particular, those who live in rural areas because access to transportation is going to be a significant problem for them. Dr. John Sweetenham: Yeah, absolutely. I think is one of the consequences of what the emerging climate changes that we've been seeing over many years now, and certainly, there has been a significant interest in the literature, and indeed, on previous ASCO Daily News podcasts regarding the impact of climate change on cancer care. And perhaps, the most immediate example of that is in terms of disaster preparedness of cancer centers. Certainly, that has been tested for you and for other centers in Florida in the last couple of weeks. How would you assess the readiness of your cancer centers to respond to disasters of this scale? Do you think there are areas of care that you've now learned need more attention, just as a direct consequence of this most recent hurricane? Dr. Eduardo Sotomayor: So, I think it's going to be location-dependent. You know, Florida is a big state. For us and other centers that are in the islands, the surge was probably the major threat for us. I mean, there is a technology now called AquaFence. So basically, there are panels that will help you, to be able to give you time to evacuate or to protect the lower floors of the cancer center of the TGH hospital as a whole. It's called AquaFence. So, we install those panels around the whole hospital, and I think that's one of the technologies. And we are going to see more and more of those technologies to try to protect or minimize the potential damage that a hurricane can cause. I mean, my prediction is that it's going to be able to support a hurricane category two, three, or even four, but you know, five - time will tell. So, we need to start thinking more about technology, that's in our case. So, there are other cancer centers that are inland in which the problem for them is going to be flooding. So, one lesson that we have learned is, there has been constant communication between all the cancer centers in this region. In the academic institutions, the University of Miami, Florida, us, Moffitt Cancer Center, but also in the community - Florida Cancer Specialists, especially, community oncology practices. And I think that if you ask me, "What would be the next step?" It will be to foster stronger communication, a stronger collaboration that involves also our community oncology practices because as you know, John, most of the cancer care now is happening close to home. Dr. John Sweetenham: Well, thanks for that. I think that's such an important message, and I should add for our listeners that you can find information about disaster resources for care providers and patients on the ASCO website, at: asco.org. Dr. Sotomayor, I just want to thank you again for giving us your time today at what must be a really busy time for you all and would like to wish you and our many colleagues in the region, especially those in the hardest hit areas of southwest Florida, all the best during difficult and uncertain times as they try to recover from the hurricane. Dr. Eduardo Sotomayor: There are so many heroes here - talking about cancer care, you know, oncologists, nurses, APPs, MAs - they left their families at home and they went and they stayed with patients. So, I am proud to say that most of them, they offered to go there. We didn't need to say you, and you, and you. And I want to thank all of those, you know, our colleagues, providers, all the team members in all the hospitals, big, medium size, also small, in the state of Florida, that they left their loved ones to be support and take care of our patients. Dr. John Sweetenham: Certainly heartwarming to hear about that kind of response. And thanks again to you, Dr. Sotomayor. And thank you to our listeners for your time today. If you value the insights that you hear on ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement. Follow today's speakers: Dr. John Sweetenham @JSweetenhamMD Dr. Eduardo Sotomayor Tampa General Cancer Institute Want more related content? Listen to our podcast on climate change and cancer: Climate Change and Cancer Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness Dr. Eduardo Sotomayor: Consulting or Advisory Role: Seattle Genetics, Genentech/Roche, Celgene, Kite Pharma, Bayer, AstraZeneca, Pharmacyclics Speakers' Bureau: Seattle Genetics, Pharmacyclics
Alan has inspired hundreds of clients over the past four decades but not by using standard coaching methods. Instead, he guides career-driven professionals down a path toward meaningful work that is not only successful but also rewarding. His first book, Leader Evolution: From Technical Expertise to Strategic Leadership, provides a clear roadmap for advancement. Burn Ladders. Build Bridges. incites a revolution to make the future of work abundantly more fulfilling. Alan has worked with leaders from the Broad Institute, Federal Reserve Bank, Hewlett Packard, Johnson and Johnson, Kite Pharma, Major League Baseball, and the United States Navy. If only he worked with some big names! He has also brought his methods to many conferences and workshops and has served as an adjunct professor in business schools across the country, where he has changed quite a few career paths and, dare we say, a few lives. He holds a BA from the University of Wisconsin, an MA from the University of North Carolina, and an Ed.D from Boston University. While his head is full of knowledge and expertise, it's what is in his heart that sets him apart as a distinctive, industry leading speaker and voice of inspiration. If you're looking to scrap the shoot-up-the-ladder corporate mindset, you've found the right guy, Find out more at: www.ladderburners.com
Will Junker, Head of Manufacturing Quality at Kite Pharma, talks to Cell & Gene: The Podcast listeners about the challenges associated with capacity planning, whether to partner with a CDMO, and why it's important to prioritize inventory over time-to-market. We also discuss why developing a better understanding of the vector manufacturing process is critical to bringing continuous and secure supply to market.
Nina is one of the up-and-coming superstars in biotech. Having just earned her PhD in bioengineering at Stanford in the Sunwoo Lab this summer, she has the scientific horsepower and storytelling ability to make a large impact on drug development, business, and the lives of patients. At the age of 8, Nina was diagnosed with an ovarian teratoma. In some ways, that shifted Nina towards a career in science and a mission to cure cancer. But while she was always interested in science, growing up in the suburbs of New York City enabled her to become world-class oboe and bassoon player as well. But in her words, she chose the research path rather than joining a conservatory because "science is a way to help other people [while] music is fun." At Williams College, she studied mathematics and biology and became interested in the progress going on in the cell therapy space, particularly CAR-T. This is around 2014 when companies like Juno Therapeutics, Novartis, and Kite Pharma were engineering patient T-cells to hone in on lymphomas. With a growing interest in bioengineering and the early clinical successes in CAR-T, Nina was compelled to join the LEAP program at Boston University to study bioengineering with a goal of engineering immune cells to target cancer. After applying to a number of graduate programs, Nina ended up at Stanford. She rotated through 5 labs: Irv Weissman, Garry Nolan, Crystal Mackall, Edgar Engleman, and John Sunwoo. These experiences ended up having a major impact on her research where she was able to have the flexibility to pursue the projects she was excited by in cell therapies and use various tools/methods she picked up from the other 4 groups in her graduate research. Early-on in grad school, her cancer relapsed and she was treated again. One thing about Nina is her grit. She was able to still move forward with her work despite all of this. Truly amazing. Her first project ended up not working out perfectly but taught Nina how to choose problems to work on. Michael Fischbach helps teach a class at Stanford, BioE 395, on this topic that Nina and I would recommend checking out. Her next project focused on studying subtypes of NK cells in tumors and generating functional data to figure out if they are a unique class of immune cells or an artifact of single-cell sequencing. After figuring out how to run an experiment with 1 month of prep, around 4 days of work, and then 3 weeks of data acquisition and analysis (shout-out to Gail for the help), Nina was able to discover a novel functionality of a new NK cell type that resembles ieILC1s, which have potent anti-tumor activity. Once she was able to show the experiment worked, Nina did the harrowing experiment another five times to verify her discovery and did an incredible job to combine various tools to map out new NK cell biology. At the end of the conversation, we discuss her new job as Head of Research at ImmuneBridge and the opportunities she sees in cell therapies. Nina is truly a role model to scientists and cancer survivors everywhere.
In this GOLD nugget, Helena looks back at thoughts shared by Aliya Omer, Vice President and Head of Global Portfolio and Program Strategy at Kite Pharma from our special International Women's Day episode. Aliya reflects on her time playing basketball in her youth and fighting for gender equality both on and off the court, some key role models in her life and the importance of listening to engage rather than to reply. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Aliya's full episode: https://www.emg-gold.com/post/podcast-international-womens-day-special Bayer in top spot for equality, diversity and inclusion: https://www.emg-gold.com/post/bayer-in-top-spot-for-equality-diversity-and-inclusion Setting the stage for a more equitable future: https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future Diversity: from ideas to action: https://www.emg-gold.com/post/diversity-from-ideas-to-action
Time to dive into the “purpose” conversation. That's the idea that we, as leaders, have an obligation, a responsibility, to help our employees find the purpose behind their jobs — the “why” behind their work. My guest on the podcast this week is Dr. Alan Patterson. He's a Business Learning Institute thought leader who has guided hundreds of clients in professional and leadership development, including the Broad Institute, Federal Reserve Bank, Hewlett Packard, Johnson and Johnson, Kite Pharma, Major League Baseball, and the United States Navy. He is a frequent conference and workshop presenter and a best-selling author whose most recent book is out now. It's called Burn Ladders, Build Bridges: Pursuing Work With Meaning And Purpose. We sat down recently and talked about how we can go about surrounding ourselves with people who will help us do work with meaning and purpose — and just as important, how we can become those types of people for others. https://www.macpa.org/podcast-burn-ladders-build-bridges/ (Read More) Resources: http://www.mentore.com/about/dr-alan-m-patterson/ (Dr. Alan Patterson) https://www.amazon.com/Burn-Ladders-Build-Bridges-Pursuing/dp/163742213X (Burn Ladders, Build Bridges: Pursuing Work With Meaning And Purpose) https://www.ladderburners.com/alan-patterson/ (Ladder Burners)
In this special bumper episode to mark International Women's Day, Helena is joined by Nikki Jones, Head of Diversity, Equity and Inclusion at the Healthcare Businesswomen's Association, to discuss the role of this global celebration within the health space. The team also speaks to Aliya Omer, Vice President and Head of Global Portfolio and Program Strategy at Kite Pharma, about how she navigated gender biases through her career. And the episode is topped off with a deep dive into GOLD features on gender parity with Isabel O'Brien, Assistant Editor – it's an episode not to be missed! If you're interested in learning more about the topic areas discussed in this episode, check out the following content: A discussion on the pandemic and gender parity https://www.emg-gold.com/post/a-discussion-on-the-pandemic-and-gender-parity Diversity: from ideas to action https://www.emg-gold.com/post/diversity-from-ideas-to-action Mind the pay gap https://www.emg-gold.com/post/mind-the-pay-gap
About Salah Kivlighn and HepaTx Corporation: My colleagues describe me as an inspiring results-driven leader with a rare blend of science and business acumen across several therapeutic classes, including oncology, autoimmunity and cardiovascular. I believe in leading with compassion and empathy; with this in mind I have built and led culturally diverse high performing teams located in countries around the world. As a commercial leader I have helped to build franchises with annual revenues in excess of 3 Billion dollars. My business experience spans the start-up sector to Fortune 100 organizations across the globe, including Merck & Co., MedImmune, Inc. (a subsidiary of AstraZeneca founded as Molecular Vaccines Inc. in 1988), AstraZeneca, Kite Pharma (a subsidiary of Gilead Sciences), NABI Biopharmaceuticals, and the United States Pharmacopeia, a nonprofit organization. As a scientist, commercial leader and global speaker, I have verified successes in oncology (mAb, cell-based, and immuno-oncology), vaccines, and cardiovascular disease treatments. My awards include the AstraZeneca CEO Award and the globally esteemed Prix Galien Award for Best Biotechnology Product (RotaTeq®). With unique and extensive experience in commercial and R&D pharma and biotech with full spectrum product life cycle responsibility, I've led pre-clinical / clinical R&D, global marketing and sales teams with international operations oversight. Most recently I oversaw all commercial aspects of seven business verticals: Small molecule generic medicine, Biologics, Dietary Supplements & Verification, Food, Excipients, Health Care Quality & Safety, and Global Education. Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.
This week, Liz is joined by Chief Executive Officer of Kite Pharma, Christi Shaw, to discuss the way she went from a child living on a farm to the CEO of a transformational cancer treatment center. Christi shares how she took the painful loss from losing her mother and sister to cancer, only to turn it into groundbreaking cell therapy technology with the ultimate goal of a cure for cancer with industry-leading pipeline and manufacturing capabilities. Follow Liz on Twitter: @LizClaman
While CAR-T cell therapies have been a promising new area of cancer treatments, they are costly to produce, have had limited success in treating solid tumors, and can carry sometimes serious side effects. Shoreline Biosciences is developing off-the-shelf natural killer and macrophage cellular immunotherapies derived from induced pluripotent stem cells for cancer, inflammatory, and genetic diseases. The company programs these cells to target and kill tumors, as well as repair tissue homeostasis. The company said its approach allows for the creation of a streamlined, affordable, and scalable manufacturing process that can deliver cell therapy treatments to patients in a faster and more cost-effective manner. We spoke to Kleanthis Xanthopoulos, co-founder and CEO of Shoreline Biosciences, about the company's off-the-shelf cell therapies, its focus on the innate immune system, and how it's leveraging its technology through recent partnerships with BeiGene and Kite Pharma.
Ali Tamaseb has spent thousands of hours manually amassing what may be the largest dataset ever collected on startups, comparing billion-dollar startups with those that failed to become one—30,000 data points on nearly every factor: number of competitors, market size, the founder's age, his or her university's ranking, quality of investors, fundraising time, and many, many more. And what he found looked far different than expected. Just to mention a few: Most unicorn founders had no industry experience; There's no disadvantage to being a solo founder or to being a non-technical CEO; Less than 15% went through any kind of accelerator program; Over half had strong competitors when starting–being first to market with an idea does not actually matter. Tamaseb tells the stories of the early days of billion-dollar startups first-hand. He includes exclusive interviews with the founders/investors of Zoom, Instacart, PayPal, Nest, Github, Flatiron Health, Kite Pharma, Facebook, Stripe, Airbnb, YouTube, LinkedIn, Lyft, DoorDash, Coinbase, and Square, venture capital investors like Elad Gil, Peter Thiel, Alfred Lin from Sequoia Capital and Keith Rabois of Founders Fund, as well as previously untold stories about the early days of ByteDance (TikTok), WhatsApp, Dropbox, Discord, DiDi, Flipkart, Instagram, Careem, Peloton, and SpaceX. Tamaseb provides counterintuitive insights and inside stories from people who have built massively successful companies. His book Super Founders is a paradigm-shifting and actionable guide for entrepreneurs, investors, and anyone interested in what makes a startup successful. Bio: Ali Tamaseb is a partner at DCVC, a VC firm in Silicon Valley with over $2 billion under management. He holds several leadership and board positions at companies across the U.S. and globally. In this episode of Trend Following Radio: Silicon Valley Startups Collecting Data Super Founders The Unicorn and the Non-Unicorn The Domain Expertise College Degree Doesn't Matter Eric Yuan and Zoom Social Media Companies
T-Cell Therapies offer enormous promise in the development of new approaches to treating cancer. A federal appeals court recently heard arguments in a patent dispute between two companies that have emerged as leaders in CAR-T technology for new cancer treatments. The patent relates to a treatment approach that uses specially altered T cells to fight cancer. In 2020 Juno Therapeutics won a $1 billion judgment against Gilead's Kite Pharma in connection with alleged infringement of U.S. Patent No. 7,446,190, entitled “Nucleic Acid Encoding Chimeric T Cell Receptors.” In this episode of the Harris Beach Podcast, partner Laura Smalley provides additional background on the case, analyzes the Circuit Court arguments, and provides her thoughts on the implications of the case and what might happen next. Related Links: Laura Smalley Bio - http://bit.ly/2uoTz2FIntellectual Law Practice Group - https://bit.ly/30dLcCU
Kite Pharma Global Head of Technical Operations Chuck Calderaro joins the Business of Biotech for a conversation on a dichotomy in the CAR T-cell supply chain: the inherent source material advantages and subsequent logistical challenges associated with the distribution of cell therapies. Calderaro discusses the implementation of manufacturing automation at Kite, the manufacturing hurdles that remain, and reflects on the company's autologous and allogeneic roadmaps.
Minimal residual disease positivity is predictive of disease progression in patients with large B-cell lymphoma treated with anti-CD19 CAR T-cells. TRANSCRIPT This JCO Podcast provides observations and commentary on the JCO article 'Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial' by Frank et al. My name is Patrick Reagan, and I am an Assistant Professor of Medicine at the Wilmot Cancer Institute, University of Rochester in Rochester, NY. My oncologic specialties are lymphoma and cellular therapy. I would like to disclose consultancy for Kite Pharma. Frank and colleagues present data from a prospective, multicenter trial examining serial testing of circulating tumor DNA in 72 patients with large B-cell lymphoma who received treatment with the anti-CD19 CAR T-cell, axicabtagene ciloleucel, abbreviated as axi-cel. These patients had circulating tumor DNA monitored in plasma prior to lymphodepletion chemotherapy, as well as at multiple times following axi-cel infusion. Ninety-six percent of patients had adequate DNA to identify a clonotype to track over time at study enrollment, and 60 patients had an adequate sample for analysis at day 28 after axi-cel infusion. There are several key findings in this study. The first key finding is that circulating tumor DNA may serve as a surrogate for tumor burden. A lower level of circulating tumor DNA was associated with both improved disease and toxicity outcomes. Patients who had a lower baseline circulating tumor DNA had improved progression-free and overall survival, as well as less severe cytokine release syndrome and immune effector cell associated neurotoxicity syndrome. A second key finding of this study is that circulating tumor DNA can serve as a marker for minimal residual disease in large B-cell lymphoma patients treated with CAR T-cells, and can be predictive of disease relapse. Seventy percent of patients who had durable response were negative for circulating tumor DNA one week following CAR T infusion. All patients with disease progression had at least one sample that was positive for minimal residual disease, and all but one were positive for minimal residual disease concurrently with radiographic progression. At day 28-post CAR T-cell treatment, negativity for minimal residual disease by circulating tumor DNA was strongly associated with improved progression-free and overall survival. A third key finding in this study was that positivity for minimal residual disease was highly predictive in patients who have a partial response or stable disease at day 28-post CAR T-cell treatment. Deepening of response over time has been reported with various CAR T-cell treatments suggesting that there are limitations of PET CT to assess response, particularly at early time points. In the patients who had stable disease or partial response who were positive for minimal residual disease at day 28 following axi-cel, 15 of 17 patients had a progression-free survival event, while only two of ten who were negative for minimal residual disease had a progression-free survival event. This study has multiple implications for future clinical research, which may influence routine clinical care over time. High tumor burden defined by the sum of product diameters or metabolic tumor volume has been associated with both treatment failure and excess toxicity with axi-cel, as well as tisagenlecleucel. As a potential surrogate for tumor burden, baseline circulating tumor DNA could be useful in determining high-risk groups to target for clinical trial participation. Additionally, this could be a stratification factor for randomized studies involving CAR T-cells. Additional studies with axi-cel as well as tisagenlecleucel and lisocabtagene maraleucel, which are also commercially available for large B-cell lymphoma, are important to confirm this observation. Management of patients who initially achieve a partial response or have stable disease at the first disease assessment is a common clinical problem in patients with large B-cell lymphoma treated with CAR T-cells. A proportion of patients with large B-cell lymphoma who initially have partial response or stable disease will go on to develop a complete response over time. This has been reported in all of the commercially available anti-CD19 CAR T-cell products. In the ZUMA-1, JULIET and TRANSCEND trials, approximately one third to one half of patients who initially had partial response or stable disease went on to achieve a complete response. Patients who ultimately have progressive disease have poor outcomes with a median overall survival of 180 days. Those who have stable or progressive disease as best response have a medial overall survival of only approximately 50 days. Predicting which patients are at risk to relapse is important given the small window of time to intervene. It would also potentially spare low risk patients from additional therapy, which may be difficult to tolerate given the acute toxicity of CAR T-cell therapy, as well as the prolonged hematologic toxicity seen in some patients. Disease progression following anti-CD19 CAR T-cell therapy is a pressing clinical problem in patients with large B-cell lymphoma and there is a need for clinical trials. Clinical trials should be considered in all patients who relapse following CAR T cell therapy. Early detection of relapse can help to facilitate enrollment prior to the development of complications related to progressive disease that may preclude their enrollment. There are now multiple clinically active, targeted therapeutics in large B-cell lymphoma, and a trial of maintenance or consolidative therapy could be considered in this population. This could target only the highest risk patients by using positivity for minimal residual disease as assessed by circulating tumor DNA as a criterion for inclusion. Alternatively, this could focus more broadly on the patients with stable disease or partial response, but given these results, outcomes by circulating tumor DNA status would be important secondary endpoints. Either way, circulating tumor DNA would be critical to the study design and interpretation of results. This concludes this JCO Podcast. Thank you for listening.
The FDA Group's CEO, Nick Capman, sits down with Tobias Kuners of Koenders, Managing Consultant at Tob Management, to discuss his integrated approach to implementing and interpreting qualitative and quantitative metrics in the GMP and non-GMP sides of a life science business. Read his full column in Pharmaceutical Online: https://www.pharmaceuticalonline.com/doc/quality-management-review-benchmarking-quantitatively-0001 Tobias has worked with Biogen, Ipsen, Thermo Fisher, Kite Pharma, and Danone, among other companies, gaining hands-on experience in engineering services, equipment qualification, maintenance, supply chain, warehousing, and distribution. He has led the design, engineering, and construction of multiple facilities to meet cGMP requirements. He performs audits, identifies gaps, and develops remediation plans, working within organizations to assist with deviation investigations and CAPA implementation and to develop scientific, risk-based solutions. You can contact him at tobias.kunersofkoenders@tobmanagement.nl. Need RA/QA/Clinical project or resourcing support? The FDA Group helps thousands of life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more and get the conversation started: www.thefdagroup.com.
What started as a viral medium article from two years ago has now turned into 'Super Founders', a book on what data reveals about billion-dollar startups. Today on the NFX Podcast we have Ali Tamaseb (partner at DCVC) talking with James Currier about his data-driven approach to understanding what really differentiates billion-dollar startups from the rest. The book includes exclusive interviews with the founders/investors of Zoom, Instacart, PayPal, Nest, Github, Flatiron Health, Kite Pharma, Facebook, Stripe, Airbnb, YouTube, LinkedIn, Lyft, DoorDash, Coinbase, and Square, venture capital investors like Elad Gil, Peter Thiel, Alfred Lin, and Keith Rabois. Ali Tamaseb has spent thousands of hours manually amassing what may be the largest dataset ever collected on startups, comparing billion-dollar startups with those that failed to become one—30,000 data points on nearly every factor: number of competitors, market size, the founder's age, his or her university's ranking, quality of investors, fundraising time, and many, many more.
Today we bring on a Bioengineer from Kite Pharma, Jonathan Villanueva, where he breaks down his thoughts on the vaccine, parent life, and life in the lab. Literally. Tune in!
In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL? Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?Presenter:Frederick L. Locke, MDCo-LeaderMoffitt Immuno-Oncology ProgramVice Chair and Associate Member Department of Blood and Marrow Transplant and Cellular ImmunotherapyResearch Director and Medical DirectorImmune Cell Therapy ProgramMoffitt Cancer CenterTampa, FloridaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program: https://bit.ly/3rDeFCV
In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?Presenter:Noopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program:http://bit.ly/3rDeFCV
Join Melissa as she has a candid conversation with Trushar Agrawal, Director at Kite Pharma.In this episode we are discussing career pivots, managing a successful career and family, and how to create a development plan that is aligned to your goals.Listen in to learn:Trushar's career journey and how he knew which pivots to makeHow to create a development plan that will help you get to where you want to beThe power of networking and how to spark new connectionsTrushar's advice for how to grow your career in the pharma/biotech industryHow to handle a pivot that you didn't choose - such as one that occurs with a company re-structureThe one thing Trushar wish he would have know when growing his careerTo apply for 1-1 coaching visit: www.melissamlawrence.comIf you love this episode - share a review on Apple Podcasts or share on social and tag me on LinkedIn, Instagram, or Facebook.
Max Tejada, PhD is Senior Director at Kite Pharma, an American biotech company and subsidiary of Gilead Sciences that develops cancer immunotherapies with a primary focus on genetically engineered adoptive T-cell therapies called CAR-T therapies. Dr. Tejada broke into the private sector by landing an industry postdoctoral fellowship at Genentech in the lab of Dr. Napoleone Ferrara, who is widely recognized for his role in developing the angiogenesis inhibitor Avastin (bevacizumab). He subsequently led teams that devised bioassays for development and high volume production of antibody-based drugs at Genentech, Gilead, and AstraZeneca as well as for cell therapies at Kite Pharma. We explore the various roles and responsibilities in R&D, the difference between “leaders versus managers”, and how you can keep on building technical expertise to match the speed of innovation in the biotech industry.Hosted by Roshan Chikarmane and Jenna Glatzer.
In early 2020, Juno Therapeutics won a $1 billion jury verdict against Gilead's Kite Pharma in connection with alleged infringement of U.S. Patent No. 7,446,190, entitled “Nucleic Acid Encoding Chimeric T Cell Receptors. In this episode, Harris Beach partner Laura Smalley discusses the implications of the Juno v. Kite pharma case, including the use of the “reasonable royalty” concept to support a large damaged award. Laura is an authority on intellectual property law and is a regular contributor to the American Intellectual Property Law Association's Biotech Buzz newsletter as well as a presenter on regulatory and IP issues for immunotherapies, including Car-T and antibody technologies. Related Links: Laura Smalley Bio - http://bit.ly/2uoTz2FIntellectual Property Law Practice Group - https://bit.ly/30dLcCUDownload Episode Transcript
On today's episode of the KGI Podcast, Sandi Mero chats with Thomas Tredennick, who is a senior manager at Kite Pharma and also owns La Verne Brewing Company, which has been the site of many student and alumni events. He is an experienced leader with a demonstrated track record in engineering, operations, marketing, and market research. Thomas earned a bachelor’s at Cornell in 2008 and then completed KGI’s Master of Business and Science program in 2010.
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, EMA, Bluebird bio, Medigene, Johnson&Johnson, Roche, Pfizer, Novartis, Merck & Co, Gsk, Bayer, Abbvie, Gilead, Eli Lilly, Amgen, Astrazeneca, Teva, Bms, Aurka Pharma, FDA, Kite Pharma, Opis.Persone: Ana Garcia-Cebrian (Sanofi), Beppe Sala (Sindaco di Milano), Massimo Balestri (Roche), Elena Acmet (Roche), Sean Gratton (Università del Missouri).Nuove terapie: fingolimod.Patologie: diabete, emicrania, sclerosi multipla.Lavoro: Research Methodology Associate, Medical Advisor.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Sanofi, EMA, Bluebird bio, Medigene, Johnson&Johnson, Roche, Pfizer, Novartis, Merck & Co, Gsk, Bayer, Abbvie, Gilead, Eli Lilly, Amgen, Astrazeneca, Teva, Bms, Aurka Pharma, FDA, Kite Pharma, Opis.Persone: Ana Garcia-Cebrian (Sanofi), Beppe Sala (Sindaco di Milano), Massimo Balestri (Roche), Elena Acmet (Roche), Sean Gratton (Università del Missouri).Nuove terapie: fingolimod.Patologie: diabete, emicrania, sclerosi multipla.Lavoro: Research Methodology Associate, Medical Advisor.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Kite Pharma, Gilead, Sangamo Therapeutics, Assogenerici, Amazon, Perrigo, Novartis, Roche, Flatiron Health, FDA, Astrazeneca, Bausch and Lomb, PRA Health Sciences, Menarini. Persone: Enrique Häusermann (Assogenerici), Susanne Schaffert (Novartis), Vincenzo Palermo (Astrazeneca), Antonio Iavarone (Besta), Anna Lasorella (Besta).Nuove terapie: durvalumab.Patologie: tumore al polmone, glioblastoma. Lavoro: Pharmacovigilance Specialist, CRA, Regulatory Affairs Officer.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Kite Pharma, Gilead, Sangamo Therapeutics, Assogenerici, Amazon, Perrigo, Novartis, Roche, Flatiron Health, FDA, Astrazeneca, Bausch and Lomb, PRA Health Sciences, Menarini. Persone: Enrique Häusermann (Assogenerici), Susanne Schaffert (Novartis), Vincenzo Palermo (Astrazeneca), Antonio Iavarone (Besta), Anna Lasorella (Besta).Nuove terapie: durvalumab.Patologie: tumore al polmone, glioblastoma. Lavoro: Pharmacovigilance Specialist, CRA, Regulatory Affairs Officer.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
It's that time of year when we begin to look back and think ahead. Starting with this week's interview, we begin a three-part review-preview series to discuss the year in biotech and what to look for in 2018. In 2017, there were exciting developments in the area of immune-oncology with the approval of the first Car-T therapies and Gilead's acquisition of Kite Pharma. As the year approached the finish line, investors got to view data from a range of studies at the American Society of Hematology meeting in Atlanta, setting the stage for 2018 when data from studies looking at combinations of immunotherapies will be closely watched. We spoke to Brad Loncar, CEO of Loncar investments, about the state of immunotherapies, what caught his attention at the ASH meeting, and what he'll be watching in 2018.
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Teva, Bayer, Menarini, Allergan, Repros Therapeutics, Novartis, FDA, Sanofi, Eli Lilly, Gilead, Kite Pharma, Ionis Pharmaceuticals, Roche.Persone: Jörg Reinhardt (Novartis), Franco Cavalli (Istituto Oncologico della Svizzera Italiana), Alberto Albanese (Humanitas).Nuove terapie: Kymriah, Admelog, Humalog, emicizumab, Yescarta.Patologie: infertilità, leucemia, diabete, emofilia A, linfoma non-Hodgkin, sclerosi laterale amiotrofica, tubercolosi, Còrea di Huntington.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Teva, Bayer, Menarini, Allergan, Repros Therapeutics, Novartis, FDA, Sanofi, Eli Lilly, Gilead, Kite Pharma, Ionis Pharmaceuticals, Roche.Persone: Jörg Reinhardt (Novartis), Franco Cavalli (Istituto Oncologico della Svizzera Italiana), Alberto Albanese (Humanitas).Nuove terapie: Kymriah, Admelog, Humalog, emicizumab, Yescarta.Patologie: infertilità, leucemia, diabete, emofilia A, linfoma non-Hodgkin, sclerosi laterale amiotrofica, tubercolosi, Còrea di Huntington.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Titan Pharmaceutical, Molteni Farmaceutici, Astaldi, NovoNordisk, Novartis, Kite Pharma, Amgen, EMA, Teva.Persone: Aniello Musella (Ice Istambul), Mads Krogsgaard Thomsen (NovoNordisk), Marco Forestiere (Amgen), André Dahinden (Amgen), Maurizio de Martino (Università di Firenze).Nuove terapie: Probuphine, Repatha, fremanezumab.Patologie: emicrania, AIDS, tumori, HPV.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Titan Pharmaceutical, Molteni Farmaceutici, Astaldi, NovoNordisk, Novartis, Kite Pharma, Amgen, EMA, Teva.Persone: Aniello Musella (Ice Istambul), Mads Krogsgaard Thomsen (NovoNordisk), Marco Forestiere (Amgen), André Dahinden (Amgen), Maurizio de Martino (Università di Firenze).Nuove terapie: Probuphine, Repatha, fremanezumab.Patologie: emicrania, AIDS, tumori, HPV.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Bayer, Loxo Oncology, ISS, EMA, Shire, FDA, Angelini, Aboca, AIFA, Novartis, Kite Pharma.Persone: Carlo Petrini (ISS), Francesco Scopesi (Shire), Oliver Mundell (GBI Research), Mario Melazzini (AIFA), Crystal Mackall (Stanford University School of Medicine’s Cancer Institute).Nuove terapie: Loxo-101, Loxo-195, pegaspargasi, Kymriah, Yescarta.Patologie: leucemia linfoblastica acuta, schizofrenia, diabete, epatite C, cancro.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Bayer, Loxo Oncology, ISS, EMA, Shire, FDA, Angelini, Aboca, AIFA, Novartis, Kite Pharma.Persone: Carlo Petrini (ISS), Francesco Scopesi (Shire), Oliver Mundell (GBI Research), Mario Melazzini (AIFA), Crystal Mackall (Stanford University School of Medicine’s Cancer Institute).Nuove terapie: Loxo-101, Loxo-195, pegaspargasi, Kymriah, Yescarta.Patologie: leucemia linfoblastica acuta, schizofrenia, diabete, epatite C, cancro.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple
Today in FirstWord:
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Today in FirstWord:
Gilead Sciences buys Kite Pharma for $12 billion in cash. Kristine Harjes and Jason Moser analyze the deal and what it means for Gilead’s future. Plus, Uber gets a new CEO (courtesy of Expedia), Fitbit rolls out a new smartwatch, and Whole Foods is now selling....Amazon Echo speakers.
Today in FirstWord:
Here's why Exelixis, Pacira Pharmaceuticals, Kite Pharma, Exact Sciences, and Portola Pharmaceuticals are up more than 50% in the first two months of 2017.
Today in FirstWord:
The 21st Century Cures Act ignites innovation with perks to biopharma and medical device makers. Also, Kite Pharma and Novartis prep plans to pitch their CAR-T cancer therapies to the FDA.
Today in FirstWord:
Today in FirstWord:
Today in FirstWord:
Today in FirstWord:
© 2020-2025 Ivy Podcast Discovery LLC
